Retatrutide, a experimental dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is showing promising results in initial patient studies. Ongoing https://kingslists.com/story22762486/retatrutide-emerging-research-and-possible-therapeutic-roles